Addressing Barriers to Recruitment in a Global cUTI Drug Study

A large pharmaceutical company chose Labcorp Drug Development to support its ongoing Phase II study evaluating patients with cUTI. Labcorp offered the sponsor extensive experience in efficiently running antibacterial trials and started by collaboratively reviewing historical epidemiological information to select 67 sites across 19 countries.